文献速递类风湿关节炎

临床实践中类风湿关节炎治疗方案的比较有效性:一项系统评价

Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2023-08-06

该系统评价检索了2001至2021年Medline及2020和2021年EULAR与ACR年会摘要,纳入68项非随机研究(排除1项偏倚风险极高者),评估生物制剂和靶向合成改善病情抗风湿药在成人类风湿关节炎中的真实世界比较有效性。多数为多中心观察性队列或登记研究,最常见比较为肿瘤坏死因子抑制剂与非肿瘤坏死因子抑制剂生物制剂,各药物间临床有效性未见明显差异。

要点

  • 各生物制剂和靶向合成改善病情抗风湿药之间临床有效性未见明显差异。
  • 最常见比较为肿瘤坏死因子抑制剂与非肿瘤坏死因子抑制剂生物制剂(35项研究)。
  • 类风湿关节炎治疗应针对个体临床特征进行定制。

核心结论

  • 该真实世界证据系统评价发现类风湿关节炎有多种有效治疗选择,但支持某一生物制剂或靶向合成改善病情抗风湿药或药物类别优于其他的证据相对较少。
  • 类风湿关节炎患者的治疗应针对个体临床特征进行定制。
  • 需进一步研究以确定特定患者亚组是否可能从特定药物类别中获益。

研究设计与样本

  • 检索Medline 2001至2021年期刊文章及Embase中2020和2021年EULAR与ACR年会摘要,纳入比较生物制剂或靶向合成改善病情抗风湿药有效性的非随机研究。
  • 共筛选1283条记录,68项研究入选数据提取,其中1项因偏倚风险极高被排除。
  • 研究间方法学异质性妨碍了荟萃分析,偏倚风险采用Cochrane非随机干预研究偏倚风险工具(ROBINS-I)评估。

主要发现

  • 多数研究为多中心观察性队列或登记研究(n=60),发表于2011至2021年(n=60)。
  • 报告的平均或中位类风湿关节炎病程为6至15年。
  • 临床实践中最常用结局为28关节疾病活动度评分(46项研究)、临床疾病活动度指数(37项研究)和健康评估问卷残疾指数(32项研究),并存在区域差异。
  • 最常见的比较为肿瘤坏死因子抑制剂与非肿瘤坏死因子抑制剂生物制剂之间(35项研究)。
  • 各生物制剂和靶向合成改善病情抗风湿药之间临床有效性未见明显差异。

临床怎么用

  • 原文结论指出类风湿关节炎患者的治疗应针对个体临床特征进行定制,但未据此给出具体推荐。

局限性

  • 研究间方法学异质性妨碍了荟萃分析。
  • 需进一步研究以确定特定患者亚组是否可能从特定药物类别中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess real-world comparative effectiveness studies of biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA) through a systematic review. METHODS: We searched Medline for journal articles (2001-2021) and Embase® for abstracts presented at the European Alliance of Associations for Rheumatology and American College of Rheumatology (ACR) 2020 and 2021 annual meetings on non-randomized studies comparing the effectiveness of b/tsDMARDs using ACR-recommended disease activity measures, measures of functional status, and patient-reported outcomes (HAQ, PROMIS PF, patient pain, Patient and Physician Global Assessment of disease activity). Methodological heterogeneity between studies precluded meta-analyses. Risk of bias was assessed using the Cochrane Risk Of Bias In Non-randomized Studies of Interventions-I tool. RESULTS: Of 1283 records screened, 68 were selected for data extraction, of which 1 was excluded due to critical risk of bias. Most studies were multicenter observational cohort/registry studies (n = 60) and were published between 2011 and 2021 (n = 60). Mean or median reported RA duration was between 6 and 15 years. Disease Activity Score in 28 joints (46 studies), Clinical Disease Activity Index (37 studies), and Health Assessment Questionnaire-Disability Index (32 studies) were the most common outcomes used in clinical practice, with regional differences identified. The most common comparison was between tumor necrosis factor inhibitors (TNFis) and non-TNFi bDMARDs (35 studies). There were no evident differences between b/tsDMARDs in clinical effectiveness. CONCLUSION: This systematic review summarizing real-world evidence from a very large number of global studies found there are many effective options for the treatment of RA, but relatively less evidence to support the use of any one b/tsDMARD or drug class over another. Treatment for patients with RA should be tailored to suit individual clinical profiles. Further research is needed to identify whether specific patient subgroups may benefit from specific drug classes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Sparks JA, Harrold LR, Simon TA, et al. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review. Semin Arthritis Rheum. 2023. PMID: 37573754. doi:10.1016/j.semarthrit.2023.152249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。